NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy Sells 4,000 Shares

NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy sold 4,000 shares of NEXGEL stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.64, for a total transaction of $14,560.00. Following the completion of the transaction, the chief executive officer now owns 378,284 shares in the company, valued at approximately $1,376,953.76. The trade was a 1.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NEXGEL Stock Performance

NASDAQ:NXGL opened at $3.54 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.51 and a quick ratio of 0.93. NEXGEL, Inc. has a fifty-two week low of $1.84 and a fifty-two week high of $5.10. The business has a 50 day moving average price of $3.86 and a 200-day moving average price of $3.19.

Hedge Funds Weigh In On NEXGEL

An institutional investor recently raised its position in NEXGEL stock. Northeast Financial Group Inc. grew its holdings in NEXGEL, Inc. (NASDAQ:NXGL) by 168.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 31,848 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Northeast Financial Group Inc. owned approximately 0.50% of NEXGEL worth $82,000 at the end of the most recent quarter. Institutional investors own 2.21% of the company’s stock.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.